Literature DB >> 11339484

Myelopathy in a previously asymptomatic HIV-1-infected patient.

W A Eyer-Silva1, I Auto, J F Pinto, C A Morais-de-Sá.   

Abstract

A wide variety of disorders of diverse pathogenic mechanisms can trigger spinal cord dysfunction in HIV-1-infected patients. The most common such condition is HIV-1-associated myelopathy (HM) which characteristically complicates advanced HIV-1 disease in patients with low CD4 cell counts and previous AIDS-defining diagnoses. We describe an unusual presentation of HM in a previously asymptomatic patient with a relatively preserved CD4 cell count (458 cells/mm3) who was even unaware of his serological status. The patient presented with a clinically severe, slowly progressive myelopathy and could not walk unassisted. Significant neurological improvement could be obtained as rapidly as within 4 weeks after the institution of an antiretroviral combination of only two nucleoside analog HIV-1 reverse transcriptase inhibitors (zidovudine and didanosine). An HIV-1 protease inhibitor was also prescribed at that point but could only be added to intensify the regimen 3 months later, when significant neurological improvement had already been recorded. We also review the disorders reported to derange spinal cord function in previously asymptomatic HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339484     DOI: 10.1007/s15010-001-0084-3

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  1 in total

1.  Human immunodeficiency virus-associated vacuolar encephalomyelopathy with granulomatous-lymphocytic interstitial lung disease improved after antiretroviral therapy: a case report.

Authors:  Kazumasa Akagi; Kazuko Yamamoto; Asuka Umemura; Shotaro Ide; Tatsuro Hirayama; Takahiro Takazono; Yoshifumi Imamura; Taiga Miyazaki; Noriho Sakamoto; Hirokazu Shiraishi; Hideaki Takahata; Yoshiaki Zaizen; Junya Fukuoka; Minoru Morikawa; Kazuto Ashizawa; Katsuji Teruya; Koichi Izumikawa; Hiroshi Mukae
Journal:  AIDS Res Ther       Date:  2020-07-09       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.